GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (XSWX:CURN) » Definitions » Capital Expenditure

Curatis Holding AG (XSWX:CURN) Capital Expenditure : CHF0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Curatis Holding AG Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Curatis Holding AG's cash flow for capital expenditures for the six months ended in Jun. 2024 was CHF0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2024 was CHF0.00 Mil.

Curatis Holding AG Capital Expenditure Historical Data

The historical data trend for Curatis Holding AG's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG Capital Expenditure Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Capital Expenditure
- - -

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capital Expenditure Get a 7-Day Free Trial - - - - -

Curatis Holding AG Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curatis Holding AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (XSWX:CURN) » Definitions » Capital Expenditure
Comparable Companies
LSE:INDV LSE:HIK LSE:EAH LSE:ANCR LSE:PXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX SZSE:300122 BGNE ALNY OCSE:GMAB BMRN
Traded in Other Exchanges
CURNz:UK 0QNS:UK
Address
Weierweg 7, Liestal, CHE, CH-4410
Website
https://www.curatis.com
Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.